The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

On average, levels of LDL-C fell by about 25 percent during the first 26 weeks in those receiving the drug.

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

LDL-C was reduced by an average of 50 percent for the 23 patients who completed the study through Week 26.

FORBES: FDA Approves Lomitapide For Homozygous Familial Hypercholesterolemia

In December 2012, the FDA approved Juxtapid (lomitapide) to reduce LDL-C, total cholesterol, apolipoprotein B, and non HDL-C in patients with HoFH.

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

His study showed Vascepa lowered C-RP by 22% and LDL-C by 6%.

FORBES: Bad Pharma And The Statin Wars

Zocor was not effective in lowering my cholestrols, LDL-C enough.

FORBES: Bad Pharma And The Statin Wars

Average reductions in LDL-C were sustained during chronic therapy.

FORBES: FDA Approves Lomitapide For Homozygous Familial Hypercholesterolemia

KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

And he says imaging studies like ENHANCE have not been proven to be any more meaningful that reductions in LDL or C-reactive protein (CRP), a marker of inflammation.

FORBES: What's Next For Vytorin?